Early circulating tumor DNA dynamics at the commencement of curative-intent radiotherapy or chemoradiotherapy for NSCLC

Mason, 2017, Treatment for non-small-cell lung cancer and circulating tumor cells, Lung Cancer Manag, 6, 129, 10.2217/lmt-2017-0019 Antonia, 2017, Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer, New Engl J Med, 377, 1919, 10.1056/NEJMoa1709937 Krebs, 2022, Practical considerations for the use of circulating tumor DNA in the treatment of patients with cancer: a narrative review, JAMA Oncol, 8, 1830, 10.1001/jamaoncol.2022.4457 Pairawan S, Hess KR, Janku F, Sanchez NS, Mills Shaw KR, Eng C, et al. Cell-free circulating tumor DNA variant allele frequency associates with survival in metastatic cancer. Clin Cancer Res. 2020;26:1924–31. Moser, 2020, On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer, npj Precis Oncol, 4 Riediger, 2016, Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients, Sci Rep, 6, 10.1038/srep33505 Tie, 2015, Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer, Ann Oncol, 26, 1715, 10.1093/annonc/mdv177 Patsch, 2019, Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA), BMC Res Notes, 12, 10.1186/s13104-019-4312-2 Walls, 2020, Early circulating tumour DNA kinetics measured by ultra-deep next-generation sequencing during radical radiotherapy for non-small cell lung cancer: a feasibility study, Radiat Oncol, 15, 10.1186/s13014-020-01583-7 Nygård, 2020, Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients - initial observations, PLoS One, 15, e0231884, 10.1371/journal.pone.0231884 Breadner, 2022, Exploitation of treatment induced tumor lysis to enhance the sensitivity of ctDNA analysis: A first-in-human pilot study, Lung Cancer, 165, 145, 10.1016/j.lungcan.2022.01.013 Weber, 2021, Dynamic changes of circulating tumor DNA predict clinical outcome in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors, JCO Precis Oncol, 1540, 10.1200/PO.21.00182 Jee, 2022, Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer, Nat Med, 28, 2353, 10.1038/s41591-022-02047-z Formenti, 2018, Radiotherapy induces responses of lung cancer to CTLA-4 blockade, Nat Med, 24, 1845, 10.1038/s41591-018-0232-2 Heitzer, 2022, Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer, ESMO Open, 7, 100399, 10.1016/j.esmoop.2022.100399